

RESEARCH REPORT



COMPANION DIAGNOSTIC MARKETS

THE FUTURE OF DIAGNOSTICS

BY APPLICATION, TECHNOLOGY AND FUNDING. WITH CUSTOMIZED
FORECASTING/ANALYSIS,
AND EXECUTIVE AND CONSULTANT GUIDES
2022-2026



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	21
1.1	Companion Diagnostic Market - Strategic Situation Analysis	22
1.2	Guide for Executives, Marketing, Sales and Business Development Staff	24
1.3	Guide for Management Consultants and Investment Advisors.....	26
2	Introduction and Market Definition	27
2.1	What are Companion Diagnostics?	28
2.2	The Personalized Medicine Revolution.....	31
2.3	Market Definition.....	33
2.3.1	Revenue Market Size.....	33
2.4	Methodology.....	34
2.4.1	Authors	34
2.4.2	Sources	35
2.5	Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic	36
2.5.1	Global Healthcare Spending	36
2.5.2	Spending on Diagnostics	37
2.5.3	Important Role of Insurance for Diagnostics.....	39
3	Market Overview.....	40
3.1	Players in a Dynamic Market.....	41
3.1.1	Academic Research Lab	42
3.1.2	Diagnostic Test Developer.....	42

3.1.3	Instrumentation Supplier	42
3.1.4	Distributor and Reagent Supplier	43
3.1.5	Independent Testing Lab.....	43
3.1.6	Public National/regional lab	44
3.1.7	Hospital lab	44
3.1.8	Physician Office Labs	44
3.1.9	Audit Body	45
3.1.10	Certification Body.....	45
3.2	Personalized Medicine and Companion Diagnostics	47
3.2.1	Basics.....	47
3.2.2	Method.....	48
3.2.3	Disease risk assessment	48
3.2.4	Applications.....	48
3.2.5	Diagnosis and intervention	49
3.2.5.1	Companion Diagnostics	50
3.2.6	Drug development and usage	50
3.2.7	Respiratory proteomics	51
3.2.8	Cancer genomics	52
3.2.9	Population screening	53
3.2.10	Challenges.....	53
3.2.11	Regulatory oversight	53
3.2.12	Intellectual property rights.....	54
3.2.13	Reimbursement policies.....	54
3.2.14	Patient privacy and confidentiality	54

3.3	Chromosomes, Genes and Epigenetics	56
3.3.1	Chromosomes	56
3.3.2	Genes.....	58
3.3.3	Epigenetics	61
3.4	Cancer Genes.....	62
3.4.1	Germline vs Somatic	64
3.4.2	Changing Clinical Role	66
3.5	Structure of Industry Plays a Part.....	67
3.5.1	New Pharmaceutical Funding Market	67
3.5.2	Economies of Scale.....	67
3.5.2.1	Hospital vs. Central Lab.....	68
3.5.3	Physician Office Labs	69
3.5.4	Physicians and POCT.....	69
4	Market Trends	71
4.1	Factors Driving Growth	72
4.1.1	Level of Care.	72
4.1.2	Immuno-oncology.....	73
4.1.3	Liability.....	73
4.1.4	Aging Population.....	73
4.2	Factors Limiting Growth	75
4.2.1	State of knowledge.....	75
4.2.2	Genetic Blizzard.....	76
4.2.3	Protocol Resistance.....	76
4.2.4	Regulation and coverage.....	76

4.3	Instrumentation and Automation	77
4.3.1	Instruments Key to Market Share	77
4.3.2	Bioinformatics Plays a Role	77
4.4	Diagnostic Technology Development	78
4.4.1	Next Generation Sequencing Fuels a Revolution.....	79
4.4.2	Single Cell Genomics Changes the Picture.	80
4.4.3	Pharmacogenomics Blurs Diagnosis and Treatment.....	81
4.4.4	CGES Testing, A Brave New World.	81
4.4.5	Biochips/Giant magneto resistance based assay.....	82
5	Companion Diagnostics Recent Developments.....	83
5.1	Recent Developments – Importance and How to Use This Section	84
5.1.1	Importance of These Developments	84
5.1.2	How to Use This Section.....	84
5.2	Burning Rock Secures Lung Cancer NGS Test Approval in China.....	84
5.3	TenSixteen Bio Developing Drugs, Companion NGS Tests.....	85
5.4	Guardant Health Plans New Comprehensive Assay.....	88
5.5	Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs.....	90
5.6	Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test	92
5.7	Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx.....	93
5.8	Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug	94
5.9	Natera Aims to Lead Market in Solid Tumor Adjuvant CDx.....	94
5.10	Oncocyte Details Expansions Plans	98
5.11	Agilent Acquires Resolution Biosciences	101
5.12	Qiagen, Inovio Expand CDx Partnership.....	104

5.13	AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance	105
5.14	NeoGenomics to Grow Through CDx Agreements, Acquisitions.....	105
5.15	Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction	111
5.16	Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform	115
5.17	FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies	116
5.18	Promega to Develop MSI Assay as CDx.....	122
5.19	Guardant Health to Develop CDx for Janssen	122
5.20	Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx	123
5.21	FDA Approval for FoundationOne®CDx.....	123
5.22	FDA finalizes CDx Guidance.....	124
5.23	QIAGEN Launches CDx Therascreen BRAF Test.....	126
6	Profiles of Key Players.....	127
6.1	10x Genomics, Inc.....	129
6.2	Abbott Diagnostics	130
6.3	AccuraGen Inc.	132
6.4	Adaptive Biotechnologies.....	133
6.5	Aethlon Medical	134
6.6	Agena Bioscience, Inc.	135
6.7	Agilent.....	137
6.8	Anchor Dx.....	139
6.9	ANGLE plc.....	140
6.10	ApoCell, Inc.....	141
6.11	ArcherDx, Inc.....	142
6.12	ARUP Laboratories.....	143

6.13	Asuragen.....	145
6.14	AVIVA Biosciences	147
6.15	Baylor Miraca Genetics Laboratories	148
6.16	Beckman Coulter Diagnostics.....	149
6.17	Becton, Dickinson and Company	150
6.18	BGI Genomics Co. Ltd	152
6.19	Bioarray Genetics.....	153
6.20	Biocartis.....	154
6.21	Biocept, Inc.....	155
6.22	Biodesix Inc.	156
6.23	BioFluidica.....	157
6.24	BioGenex	158
6.25	BioIVT	160
6.26	Biolidics Ltd.....	161
6.27	bioMérieux Diagnostics.....	162
6.28	Bioneer Corporation	165
6.29	Bio-Rad Laboratories, Inc.....	167
6.30	Bio-Reference Laboratories.....	169
6.31	Bio-Techne	170
6.32	Bioview	172
6.33	Bolidics	173
6.34	Boreal Genomics.....	174
6.35	Bristol-Myers Squibb.....	175
6.36	Cancer Genetics.....	177

6.37	Caris Molecular Diagnostics	179
6.38	Castle Biosciences, Inc.	180
6.39	CellMax Life	181
6.40	Cepheid (now Danaher)	182
6.41	Charles River Laboratories.....	183
6.42	Chronix Biomedical.....	184
6.43	Circulogene.....	185
6.44	Clinical Genomics	186
6.45	Cynvenio.....	187
6.46	Cytolumina Technologies Corp.	188
6.47	CytoTrack.....	189
6.48	Datar Cancer Genetics Limited.....	190
6.49	Diagnologix LLC.....	191
6.50	Diasorin S.p.A.	192
6.51	Enzo Life Sciences, Inc.	193
6.52	Epic Sciences.....	195
6.53	Epigenomics AG.....	196
6.54	Eurofins Scientific	197
6.55	Exosome Diagnostics	199
6.56	Exosome Sciences.....	200
6.57	Fabric Genomics.....	201
6.58	Fluidigm Corp	202
6.59	Fluxion Biosciences.....	203
6.60	Foundation Medicine	204

6.61	Freonome.....	205
6.62	GeneFirst Ltd.....	207
6.63	Genetron Health (Beijing) Co., Ltd.	208
6.64	Genomic Health.....	209
6.65	GenomOncology.....	210
6.66	GILUPI Nanomedizin.....	211
6.67	Grail, Inc.....	212
6.68	Guardant Health.....	213
6.69	HaliuDx.....	214
6.70	HansaBiomed.....	215
6.71	HeiScreen.....	216
6.72	Helomics.....	217
6.73	Horizon Discovery.....	218
6.74	HTG Molecular Diagnostics.....	220
6.75	iCellate.....	221
6.76	Illumina.....	222
6.77	Incell Dx.....	223
6.78	Inivata.....	224
6.79	Integrated Diagnostics.....	225
6.80	Invivogen.....	228
6.81	Invivoscribe.....	229
6.82	Janssen Diagnostics.....	230
6.83	MDNA Life SCIENCES, Inc.....	231
6.84	MDx Health.....	232

6.85	Menarini Silicon Biosystems.....	233
6.86	Millipore Sigma	234
6.87	Miltenyi Biotec	235
6.88	MIODx.....	236
6.89	miR Scientific.....	237
6.90	Molecular MD	238
6.91	MyCartis	239
6.92	Myriad Genetics/Myriad RBM	240
6.93	NantHealth, Inc.	241
6.94	Natera	242
6.95	NeoGenomics	243
6.96	New Oncology	244
6.97	Novogene Bioinformatics Technology Co., Ltd.....	245
6.98	Oncocyte.....	247
6.99	OncoDNA	248
6.100	Ortho Clinical Diagnostics	249
6.101	Oxford Nanopore Technologies	250
6.102	Panagene.....	251
6.103	Perkin Elmer.....	252
6.104	Personal Genome Diagnostics.....	254
6.105	Personalis.....	255
6.106	Precipio	256
6.107	PrecisionMed	257
6.108	Promega	258

6.109	Qiagen Gmbh	260
6.110	Rarecells SAS.....	262
6.111	RareCyte.....	263
6.112	Roche Molecular Diagnostics	264
6.113	ScreenCell	266
6.114	Sense Biodetection.	267
6.115	Serametrix	268
6.116	Siemens Healthineers	269
6.117	Silicon Biosystems.....	272
6.118	simfo GmbH	273
6.119	Singlera Genomics Inc.....	274
6.120	Singulomics	275
6.121	SkylineDx	277
6.122	Stratos Genomics	278
6.123	Sysmex Inostics.....	279
6.124	Tempus Labs, Inc.	280
6.125	Thermo Fisher Scientific Inc.....	281
6.126	Thrive Earlier Detection	283
6.127	Todos Medical	284
6.128	Trovagene.....	285
6.129	Volition	286
6.130	Vortex Biosciences	287
7	The Global Market for Companion Diagnostics	288
7.1	Global Market Overview by Country	289

7.1.1	Table – Global Market by Country.....	289
7.1.2	Chart - Global Market by Country.....	290
7.2	Global Market by Application - Overview.....	291
7.2.1	Table – Global Market by Application	291
7.2.2	Chart – Global Market by Application – Base/Final Year Comparison	292
7.2.3	Chart – Global Market by Application – Base Year	293
7.2.4	Chart – Global Market by Application – Final Year.....	294
7.2.5	Chart – Global Market by Application – Share by Year.....	295
7.3	Global Market Funding Source - Overview	296
7.3.1	Table – Global Market by Funding Source.....	296
7.3.2	Chart – Global Market Funding Source – Base/Final Year Comparison	297
7.3.3	Chart – Global Market Funding Source – Base Year	298
7.3.4	Chart – Global Market Funding Source – Final Year.....	299
7.3.5	Chart – Global Market Funding Source – Share by Year	300
7.4	Global Market Technology - Overview	301
7.4.1	Table – Global Market by Technology	301
7.4.2	Chart – Global Market Technology – Base/Final Year Comparison.....	302
7.4.3	Chart – Global Market Technology – Base Year.....	303
7.4.4	Chart – Global Market Technology – Final Year	304
7.4.5	Chart – Global Market Technology – Share by Year.....	305
8	Global Companion Diagnostic Markets – By Application.....	306
8.1	Oncology.....	307
8.1.1	Table Oncology – by Country	307
8.1.2	Chart - Oncology Growth.....	308

8.2	Neurology	309
8.2.1	Table Neurology – by Country.....	309
8.2.2	Chart - Neurology Growth.....	310
8.3	Cardiology.....	311
8.3.1	Table Cardiology – by Country	311
8.3.2	Chart - Cardiology Growth.....	312
8.4	Other Application	313
8.4.1	Table Other Application – by Country.....	313
8.4.2	Chart - Other Application Growth	314
9	Global Companion Diagnostic Markets – Funding Source	315
9.1	Global Market Pharmaceutical.....	316
9.1.1	Table Pharmaceutical – by Country.....	316
9.1.2	Chart - Pharmaceutical Growth	317
9.2	Global Market Venture.....	318
9.2.1	Table Venture – by Country.....	318
9.2.2	Chart - Venture Growth	319
9.3	Global Market Clinical.....	320
9.3.1	Table Clinical – by Country.....	320
9.3.2	Chart - Clinical Growth	321
9.4	Global Market Other Funding	322
9.4.1	Table Other Funding – by Country.....	322
9.4.2	Chart - Other Funding Growth	323
10	Global Companion Diagnostic Markets – Technology.....	324
10.1	Global Market Next Generation Sequencing.....	325

10.1.1	Table Next Generation Sequencing – by Country	325
10.1.2	Chart - Next Generation Sequencing Growth.....	326
10.2	Global Market PCR	327
10.2.1	Table PCR – by Country	327
10.2.2	Chart - PCR Growth.....	328
10.3	Global Market IHC/ISH.....	329
10.3.1	Table IHC/ISH – by Country.....	329
10.3.2	Chart - IHC/ISH Growth	330
10.4	Global Market Other Technology.....	331
10.4.1	Table Other Technology – by Country.....	331
10.4.2	Chart - Other Technology Growth	332
11	Appendices.....	333
11.1	United States Medicare System: January 2022 Clinical Laboratory Fees Schedule .	334
11.2	Pharmacogenomic Biomarkers in Drug Labeling.....	438

Table of Tables

Table 1 Market Players by Type	41
Table 2 The Base Pairs.....	59
Table 3 Five Factors Driving Growth.....	72
Table 4 Four Factors Limiting Growth	75
Table 5 Key Diagnostic Laboratory Technology Trends	78
Table 6 Next Generation Sequencing Technologies – Speed and Cost	79
Table 7 Global Companion Diagnostic Market by Region.....	289
Table 8 Global Market by Application	291
Table 9 Global Market by Funding Source	296
Table 10 Global Market by Technology	301
Table 11 Oncology by Country	307
Table 12 Neurology by Country.....	309
Table 13 Cardiology by Country	311
Table 14 Other Application by Country.....	313
Table 15 Pharmaceutical by Country	316
Table 16 Venture by Country.....	318
Table 17 Clinical by Country.....	320
Table 18 Other Funding by Country	322
Table 19 Next Generation Sequencing by Country	325
Table 20 PCR by Country	327
Table 21 IHC/ISH by Country.....	329
Table 22 Other Technology by Country.....	331

Table 23 2022 Clinical Laboratory Fee Schedule 334

Table 24 Pharmacogenomic Biomarkers 438

Table of Figures

Figure 1 FDA Approved Companion Diagnostics.....	30
Figure 2 Global Health Care Spending.....	37
Figure 3 The Lab Testing Pie	38
Figure 4 DNA Strands and Chromosomes	56
Figure 5 Karyogram of Human Chromosomes.....	57
Figure 6 Size of Various Genomes	60
Figure 7 Germline vs Somatic Mutations.....	64
Figure 8 Comparing Genomic Diagnostic and Traditional Testing	66
Figure 9 Percentage of World Population Over 65.....	73
Figure 10 Base Year Country Market Share Chart	290
Figure 11 CDx Market by Application - Base vs. Final Year	292
Figure 12 CDx Market by Application Base Year	293
Figure 13 CDx Market by Application Final Year.....	294
Figure 14 Application Type Share by Year.....	295
Figure 15 Funding Source – Base vs. Final Year	297
Figure 16 Funding Source Market Base Year	298
Figure 17 Funding Source Market Final Year	299
Figure 18 Funding Source Share by Year	300
Figure 19 Technology – Base vs. Final Year.....	302
Figure 20 Technology Market Base Year	303
Figure 21 Technology Market Final Year.....	304

Figure 22 Technology Share by Year.....	305
Figure 23 Oncology Growth	308
Figure 24 Neurology Growth.....	310
Figure 25 Cardiology Growth	312
Figure 26 Other Application Growth.....	314
Figure 27 Pharmaceutical Growth	317
Figure 28 Venture Growth.....	319
Figure 29 Clinical Growth.....	321
Figure 30 Other Funding Growth	323
Figure 31 Next Generation Sequencing Growth.....	326
Figure 32 PCR Growth	328
Figure 33 IHC/ISH Growth.....	330
Figure 34 Other Technology Growth.....	332